We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Subscribe To Our Newsletter & Stay Updated
